{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:05:33Z","timestamp":1761897933302},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.03.031","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:25:09Z","timestamp":1711697109000},"page":"148-153","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia"],"prefix":"10.1016","volume":"237","author":[{"given":"Caroline","family":"Dix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyen A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.03.031_bb0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12959-016-0096-y","article-title":"Individualised prophylaxis for optimising haemophilia care: can we apply this to both developed and developing nations?","volume":"14","author":"Poon","year":"2016","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2024.03.031_bb0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"Hassan","year":"2021","journal-title":"J. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.031_bb0015","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/bloodadvances.2018018226","article-title":"A cross-sectional analysis of cardiovascular disease in the haemophilia population","volume":"2018","author":"Sood","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.03.031_bb0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2010.02463.x","article-title":"Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience from a single haemophilia treatment centre in the United States (US)","volume":"174","author":"Sharathkumar","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.03.031_bb0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/hae.12445","article-title":"Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe","volume":"20","author":"Schutgens","year":"2014","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2024.03.031_bb0030","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1538-7836.2006.01808.x","article-title":"Mortality and causes of death in patients with haemophilia, 1992-2001: a prospective cohort study","volume":"4","author":"Plug","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.03.031_bb0035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/hc3501.094232","article-title":"Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency","volume":"104","author":"Sramek","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.03.031_bb0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0609.2012.01835.x","article-title":"History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia","volume":"89","author":"Van de Putte","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2024.03.031_bb0045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.03.031_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/CRD.0000000000000045","article-title":"Consensus review of the treatment of cardiovascular disease in people with haemophilia A and B","volume":"23","author":"Ferraris","year":"2015","journal-title":"Cardiol. Rev."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.031_bb0055","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jth.13674","article-title":"Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists","volume":"15","author":"de Koning","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.031_bb0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MBC.0000000000000678","article-title":"Thrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observed","volume":"29","author":"Rigano","year":"2018","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2024.03.031_bb0065","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies","volume":"19","author":"Ninivaggi","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.03.031_bb0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2516.2005.01107.x","article-title":"Thrombin generation and phenotypic correlation in haemophilia A","volume":"11","author":"Beltran-Miranda","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.03.031_bb0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2516.2009.02190.x","article-title":"Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy","volume":"16","author":"Gilmore","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.03.031_bb0080","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2516.2009.01994.x","article-title":"Thrombin generation and bleeding in haemophilia A","volume":"15","author":"Brummel-Ziedins","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.03.031_bb0085","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/j.thromres.2013.04.004","article-title":"Investigation of the phenotype heterogeneity in severe haemophilia A using thromboelastography, thrombin generation, and thrombodynamics","volume":"131","author":"Tarandovskiy","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.03.031_bb0090","article-title":"In patients with haemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype","volume":"7","author":"Verhagen","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.03.031_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/hae.14261","article-title":"Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data","volume":"27","author":"Misgav","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2024.03.031_bb0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a haemophilia a model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.031_bb0105","article-title":"The effect of emicizumab and bypassing agents in patients with haemophilia \u2013 an in vitro study","volume":"5","author":"Schulz","year":"2021","journal-title":"RPTH"},{"issue":"13","key":"10.1016\/j.thromres.2024.03.031_bb0110","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.03.031_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia a with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.03.031_bb0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in haemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.03.031_bb0125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2141.2008.07267.x","article-title":"Thrombin generation testing in routine clinical practice: are we there yet?","volume":"142","author":"Van Veen","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2024.03.031_bb0130","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/jcm9072018","article-title":"Delayed thrombin generation is associated with minor bleedings in venous thromboembolism patients on rivaroxaban: usefulness of calibreted automated thrombography","volume":"9","author":"Zalewiski","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.031_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.031_bb0140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ijlh.13618","article-title":"Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants","volume":"43","author":"Metze","year":"2021","journal-title":"Int. J. Lab. Haematol."},{"key":"10.1016\/j.thromres.2024.03.031_bb0145","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH05-10-0685","article-title":"Age-dependency of thrombin generation measured by means of a calibrated automatic thrombography (CAT)","volume":"95","author":"Haidl","year":"2006","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:20:32Z","timestamp":1714108832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":29,"alternative-id":["S0049384824001117"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.031","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}